JEFFREY HAMBY: Open Payments
NPI 1831178524 · VAN BUREN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$569 in 37 payments from 10 companies in 2025. Trend: 2023 $626 · 2024 $410 · 2025 $569
Food & beverage: $569
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $189 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $151 |
| Amgen Inc. | 4 | $62 |
| Corium, LLC | 2 | $46 |
| Novo Nordisk Inc | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| PFIZER INC. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: CAPLYTA, VRAYLAR, UBRELVY, OTEZLA, Azstarys, Ozempic, HETLIOZ, BREZTRI.
Industry payments across AR — which companies pay providers there.
